The key role of Shenyan Kangfu tablets, a Chinese patent medicine for diabetic nephropathy: study protocol for a randomized, double-blind and placebo-controlled clinical trial

BACKGROUND: Diabetic nephropathy (DN) is a major microvascular complication with diabetes. In China, an estimated 34.7 percent of people diagnosed with diabetes have renal complications and a further 50 percent die of renal failure. Hence, identification of alternative treatments for these patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hui, Mu, Wei, Zhai, Jingbo, Xing, Dongmei, Miao, Shujie, Wang, Jia, Deng, Yueyi, Wang, Niansong, Chen, Hongyu, Yang, Hongtao, He, Xuehong, Shang, Hongcai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3679981/
https://www.ncbi.nlm.nih.gov/pubmed/23738508
http://dx.doi.org/10.1186/1745-6215-14-165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3679981/
https://www.ncbi.nlm.nih.gov/pubmed/23738508
http://dx.doi.org/10.1186/1745-6215-14-165

Ejemplares similares